Impact of IL-2 and IL-2R SNPs on Proliferation and Tumor-killing Activity of Lymphokine-Activated Killer Cells from Healthy Chinese Blood Donors

Li, Yan; Meng, Fan-Dong; Tian, Xin; Sui, Cheng-Guang; Liu, Yun-Peng; Jiang, You-Hong

추천

검색

자료유형: 학술저널

저자정보: Li, Yan (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) Meng, Fan-Dong (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) Tian, Xin (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) Sui, Cheng-Guang (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) Liu, Yun-Peng (Oncology, The First Affiliated Hospital of China Medical University) Jiang, You-Hong (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제18호

발행연도: 2014.1

수록면: 7,965 - 7,970 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

One of the goals of tumor immunotherapy is to generate immune cells with potent anti-tumor activity through in vitro techniques using peripheral blood collected from patients. However, cancer patients generally have poor immunological function. Thus using patient T cells, which have reduced in vitro proliferative capabilities and less tumor cell killing activity to generate lymphokine-activated killer (LAK) cells, fails to achieve optimal clinical efficacy. Interleukin-2 (IL-2) is a potent activating cytokine for both T cells and natural killer cells. Thus, this study aimed to identify optimal donors for allogeneic LAK cell immunotherapy based on single nucleotide polymorphisms (SNP) in the IL-2 and IL-2R genes. IL-2 and IL-2R SNPs were analyzed using HRM-PCR. LAK cells were derived from peripheral blood mononuclear cells by culturing with IL-2. The frequency and tumor-killing activity of LAK cells in each group were analyzed by flow cytometry and tumor cell killing assays, respectively. Regarding polymorphisms at IL-2-330 (rs2069762) T/G, LAK cells from GG donors had significantly greater proliferation, tumor-killing activity, and IFN-${\gamma}$ production than LAK cells from TT donors (P<0.05). Regarding polymorphisms at IL-2R rs2104286 A/G, LAK cell proliferation and tumor cell killing were significantly greater in LAK cells from AA donors than GG donors (P<0.05). These data suggest that either IL-2-330(rs2069762)T/G GG donors or IL-2R rs2104286 A/G AA donors are excellent candidates for allogeneic LAK cell immunotherapy.

#NK #LAK #IL-2-330 #rs2069762)T/G #IL-2R #rs2104286)A/G #blood donors #killer cells

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요